

# OXFORD VACMEDIX UK Ltd


## A new approach to cancer treatment




- Spin-out from Oxford University founded in 2012
- Licensed patented technology from Oxford University and Harvard
- Focus on Immuno-oncology therapeutic vaccines - additional opportunities in Infectious diseases, in Diagnostics and as Adoptive Cell Therapy
- Series A \$12.5M from angel investors in China and from Cancer ROP – listed biopharma company in South Korea in 2018
- Company based in Oxford, UK – offices at Oxford Science Park, research labs in University of Oxford Department of Oncology
- Strong partnership working and grant funding - close collaborations with: Changzhou Bioscience (CBI), MJ Cell Bio in South Korea, CHAIN Biotech, Imperial College London and University of Oxford

# Recombinant overlapping peptides – generating Cytotoxic T Cells


## Recombinant Overlapping Peptides



## Preclinical results OVM-200 (n=10)



# Development Plan - overview



Note: timelines under constant review

# Commercial and Patient Impact

## Patient Impact

- Significant improvement on current immunotherapy standard of care for solid tumours such as NSCLC, Prostate and Breast
- Builds on patient's own immune system
- Can be used early in treatment
- Improved efficacy/lower side effects

## Commercial Impact

- Attractive therapeutic treatment for wide range of major tumours
- Significant potential for combination with current and future immunotherapy agents
- Cost effective to manufacture
- Platform technology with strong pipeline potential for new vaccine candidates, including those for infectious diseases

# Strategy and Investment

- Building company value by:
  - developing lead cancer vaccines to Phase 2
  - showing efficacy in combination with immune oncology agents
  - developing pipeline through research collaborations
  - adding to and strengthening intellectual property
- License out other applications of ROP technology where appropriate
- Exit after Phase 2 with trade sale or IPO, in 4-5 years

**Currently seeking investment of \$10m plus on pre-money valuation of \$38m, to advance OVM200 into Phase 2 and OVM100 into Phase 1**